Senior Scientist, Auto-Immunity

COMPANY DESCRIPTION

• IPO, clinical stage biotech with lead asset in Ph 1 and potential for first-in-class mechanism
• First precision medicine approach to GI therapeutics, with platform attracting strong partners
• Global exclusive license to Cedars-Sinai's GI biobank and bioinformatics platform
• Fully capitalized with top-tier investor syndicate

Prometheus is a IPO biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of inflammatory bowel disease (IBD). The company's precision medicine platform, Prometheus 360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is a spin out of Cedars-Sinai Medical Center and partners with the hospital system for its biospecimens, clinical data, and bioinformatics.

The company is led by an exceptional management team bringing deep experience in GI and autoimmune therapies. CEO Mark McKenna joined in 2019 to refocus the organization around a precision therapeutics strategy after orchestrating a successful turnaround effort at Salix Pharmaceuticals. Mark and the executive team are guided by Prometheus' board of directors, led by Chairman Tachi Yamada, M.D., and a scientific advisory board composed of key opinion leaders in IBD, including Stephan Targan, M.D., William Sandborn, M.D. and Dermot P. McGovern, M.D., Ph.D.

The company recently secured a $130 million Series D financing with a top-tier syndicate and is attracting best-in-class collaboration partners such as Takeda and Dr. Falk. With a lead therapeutic program in Phase 1 studies and a robust emerging pipeline, the company is seeking a best-in-class immunologist to lead all of Prometheus' preclinical development efforts and be accountable for delivering a sustainable pipeline of drug candidates, from target validation through IND submission.


WE ARE SEEKING:

• A Ph.D. in Immunology or equivalent post-graduate degree with subsequent experience in immunology. Prior industry experience is a plus but is not required, post-doctoral experience strongly preferred.
• Familiar with emerging new science, technologies and models relevant to the evaluation of inflammation and fibrosis.
• Confident working under BSL2 aseptic conditions. Experience working with primary cells, PBMCs, ex-vivo human and/or animal tissue cultures, such as organoids and explants, desirable.
• Experienced with cell based assays, including primary immune cell assays, multiplex-cytokine analysis and mechanism of action studies.
• Working knowledge of common animal models of fibrosis and auto-immunity. Experience with humanized and transgenic models desirable.
• Hands-on experience with immunophenotyping, flow cytometry panel design, techniques, and data analysis. Experience with CYTOF and single cell omics a plus.
• Self-motivated with excellent problem-solving, organizational and communication skills.
• Demonstrated ability to work as part of a team to execute experimental plans and deliver results. Prior involvement with projects performed in collaboration between multiple laboratories a plus.
• Capable to independently investigate new emerging science based on published literature and to establish new models and approaches

All qualified applicants are considered for employment without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability, veteran status or other protected class.